Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis 2022-05-24 19:00
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis 2022-05-24 19:00
Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business 2022-04-07 07:30
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis 2022-04-06 08:00
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer 2022-03-31 08:00
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential 2022-03-30 08:00
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021 2022-03-29 06:30
Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022 2022-03-15 09:00
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea 2022-03-14 08:00
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial 2022-03-10 19:05
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer 2022-02-07 08:00
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide 2022-01-14 08:00
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer 2022-01-10 21:35
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer 2022-01-04 08:00
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program 2021-12-20 20:55
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy 2021-12-16 08:49
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea 2021-12-15 08:00
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant 2021-12-01 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
1 3 4 5 6 7